The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...

The RAMOSE and RELAY trials revealed the capacity and constraints of combination therapy with ramucirumab (Cyramza) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The phase II RAMOSE ...

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...

The company said the combo could help overcome resistance to EGFR inhibitors in patients whose tumors harbor the mutation.

The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...

A new study, led by Prof. Liu from the department of pharmacy, University of Electronic Science and Technology of China, discovered that the extracellular cell matrix (ECM) could induce the drug ...

For the purpose of clarity, the signaling pathways can be discussed in isolation. However, in reality there is considerable cross-talk between pathways, with parallel or upstream input from other ...

The Phase 1b program was initiated with the NXP900 single agent (monotherapy) study following the successful completion of a Phase 1a dose escalation study in patients with advanced solid tumors and a ...